IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Official title

A Phase Ib/II Clinical Trial to Evaluate the Anti-tumor Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Anti-PD-1/L1 Antibody and Chemotherapy as First-line Treatment in Extensive-stage Small Cell Lung Cancer

Overview

This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).

Detailed description

This study consists of 2 parts: 1) Phase Ib-Dose Confirmation part: To assess the PK parameters, safety and recommended phase II dose (RP2D) of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug), platinum (carboplatin is proposed as the combination drug) and etoposide as the first-line treatment in ES-SCLC. 2) Phase II-Dose Expansion part: To assess the antitumor efficacy, safety and tolerability in the experimental group of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to the control group of Tislelizumab in combination with carboplatin and etoposide as the first-line treatment in ES-SCLC.

Interventions

• Drug IN10018
  orally taken once daily
• Drug Tislelizumab
  200mg D1, Q3W, intravenously
• Drug Carboplatin
  AUC 5 mg/ml/min, D1, Q3W, intravenously
• Drug Etoposide
  Etoposide 100 mg/m2, D1-D3, Q3W, intravenously

Primary outcome measures

• To identify the Recommended phase II dose (RP2D) of IN10018 in combination with Tislelizumab, Carboplatin and Etoposide in first-line ES-SCLC. [Time frame: Up to 3 years]
• Progress free survival (PFS) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR based on RECIST 1.1 [Time frame: Up to 3 years]

Secondary outcome measures (12)

• PFS of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per investigator based on RECIST 1.1 [Time frame: Up to 3 years]
• Objective response rate (ORR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1. [Time frame: Up to 3 years]
• Duration of objective response (DOR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1. [Time frame: Up to 3 years]
• Disease Control Rate (DCR) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC per BICR and investigator based on RECIST 1.1 [Time frame: Up to 3 years]
• Overall survival (OS) of IN10018 in combination with Tislelizumab, carboplatin and etoposide as compared to Tislelizumab in combination with carboplatin and etoposide in first-line ES-SCLC. [Time frame: Up to 3 years]
• Number of patients with adverse event [Time frame: Up to 3 years]
• PK: AUC of IN10018 following single dose administration and at steady state [Time frame: Up to 3 years]
• PK: Cmax of IN10018 following single dose administration and at steady state [Time frame: Up to 3 years]
• PK: Ctrough of IN10018 following single dose administration and at steady state [Time frame: Up to 3 years]
• PK: Tmax of IN10018 following single dose administration and at steady state [Time frame: Up to 3 years]
• PK: t1/2 of IN10018 following single dose administration and at steady state [Time frame: Up to 3 years]
• PK: CL/F of IN10018 following single dose administration and at steady state [Time frame: Up to 3 years]

Eligibility criteria

Inclusion criteria

• Male or female aged 18-75 years old at the time of signing informed consent.
• Be able to understand and be willing to sign informed consent.
• Histologically confirmed ES-SCLC (according to the Veterans Administration Lung Study Group (VALG) staging system), which is not suitable for locally radical therapy.
• Has not received any systemic antitumor therapy for ES-SCLC.
• Has at least one measurable tumor lesion per RECIST 1.1.
• Has an ECOG performance status of 0 or 1.
• Estimated life expectancy is more than 3 months.
• Has adequate organ function of bone marrow, liver, kidney, and coagulation. Relative laboratory tests must be performed within 7 days prior to first dose of study treatment/randomization.
• AEs due to prior antitumor therapy must be recovered to ≤ Grade 1 (CTCAE v5.0) or a steady state as assessed by investigators
• Subjects (male and female) with childbearing potential must agree to use contraception during the treatment phase and through 3 months after the last dose of study treatment.

Exclusion criteria

• Has known active or untreated central nervous system (CNS) metastases, and/or carcinomatous meningitis.
• Spinal cord compression without surgery and/or radiation therapy, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for at least 7 days prior to the first dose of study treatment/randomization.
• Pleural, pericardial or abdominal effusion that are clinically symptomatic and require puncture or drainage.
• Symptomatic hypercalcemia.
• Malignancies other than the study disease within 3 years prior to the first dose of study treatment/randomization.
• Have received palliative radiotherapy for bone metastasis within 14 days prior to the first dose of study treatment/randomization.
• Have had allogeneic haematopoietic stem cell transplantation or organ transplantation.
• History of active autoimmune disease required systemic treatment (including but not limited to drugs for disease control, corticosteroids, or immunosuppressive drugs) within the past 2 years.
• Have an immunodeficiency disorder or have received systemic steroid therapy (prednisone or equivalent corticosteroid > 10 mg/day) or other immunosuppressants within 7 days prior to the first dose of study treatment/randomization.
• History of idiopathic pulmonary fibrosis, idiopathic pneumonia and organizing pneumonia, and interstitial pneumonitis or active pneumonia diagnosed per imaging examination at baseline.
• Have had FAK inhibitors treatment.
• Has a history of major cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment/randomization.
• Have malabsorption syndrome or cannot take study drugs orally.
• Any active infection requiring systemic therapy within 14 days prior to the first dose of study treatment.
• Active pulmonary tuberculosis
• Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
• Known hypersensitivity or allergy to IN10018, anti-PD-1/L1 monoclonal antibodies, carboplatin or etoposide or to their drug components.
• Pregnant or lactating women or are expected to be pregnant or lactating during study treatment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 3 centers

• Shandong Province Cancer Hospital — Jinan
• Tianjin Medical University Cancer Institute & Hospital — Tianjin
• Henan Provincial People's Hospital — Zhengzhou

Identifiers

NCT: NCT06030258 · IN10018-019

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗